Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer’s disease-Reference-Cited by-同舟云学术

Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer’s disease

Published:2016-03-30 Issue:332 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Liu Chia-Chen¹,Zhao Na¹,Yamaguchi Yu²,Cirrito John R.³,Kanekiyo Takahisa¹,Holtzman David M.³,Bu Guojun¹⁴

Affiliation:

1. Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.

2. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.

3. Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.

4. Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361100, China.

Abstract

Deleting neuronal heparan sulfates in a mouse model of Alzheimer’s disease results in faster Aβ clearance, reduced Aβ aggregation, and less amyloid pathology.

Funder

Alzheimer's Association

Cure Alzheimer's Fund

NIH

Mayo Clinic CRM (Center for Regenerative Medicine) Career Development Award

American Heart Association

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference80 articles.

1. The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics